Please login to the form below

Not currently logged in
Email:
Password:

Duaklir

This page shows the latest Duaklir news and features for those working in and with pharma, biotech and healthcare.

Circassia seeks shift to AIM after failing LSE criteria

Circassia seeks shift to AIM after failing LSE criteria

Duaklir (aclidinium/formoterol) which is under regulatory review in the US with a verdict due by the end of March. ... The agreement between Circassia and AZ also includes a deferred Tudorza option payment of $20m payable upon approval of Duaklir, plus a

Latest news

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    AstraZeneca will complete the development of Duaklir (for which Circassia will contribute $462.5m) and will manufacture and supply the products. ... 250. AstraZeneca. Circassia Pharmaceuticals. Strategic collaboration. Tudorza (marketed) and Duaklir

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Eklira and Duaklir. Business unit acquisition. 3, 075. Pfizer / Merck KGaA.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....